Calox de Costa Rica S.A. (“Calox” or the “Company”)
Category B projects have potential environmental and/or social impacts and risks that are less adverse than those of a Category A and which are generally limited to the project site, largely reversible and can be mitigated via measures that are readily available and feasible to implement in the context of the operation.
Projected date at which a project will be put forward for the Board of Executive Directors’ approval.
Projected board date
Alvarado Blando, Gloriana
USD $ 14,000,000
USD $ 14,000,000
Project scope and objective
This transaction consists of a long-term corporate loan of up to US$14 million to Calox de Costa Rica S.A. ("CALOX" or the "Company"). CALOX is a company that has operated for more than 25 years in Central America and the Caribbean, dedicated to the production, distribution, and sale of mainly generic pharmaceutical products.
The proposed financing includes two main objectives: the first consists of the acquisition of the current plant to make improvements in infrastructure and energy efficiency, which will allow it to become certified and expand its production capacity in the medium term; the second objective consists of providing medium-term financing for permanent working capital, to enhance: (i) the expansion of medicines under its own brand ("Xaikus"); (ii) the expansion into the South American market; and (iii) continuing research and development of new products, as well as strengthening its presence in the Central American market with drugs attending to the health crisis caused by the COVID-19 pandemic.
For inquiries, comments and information requests about the projectRequest information
Alternatively, you may also use the following contact information:
Andrés Finol Wardrop
Chief Executive Officer
IDB Invest Contact
1350 New York Ave NW, Washington, DC 20005